Phase 2 Lymphoma Trial, Recruiting NCT06735495 Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06735495
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a B-cell blood cancer (such as B-cell leukemia or B-cell lymphoma) that has come back or has not responded to previous treatments, confirmed by a tissue or pathology test.
  • For leukemia patients, at least one of these applies: the cancer came back within 6 months of first going into remission; the cancer never fully responded after 2 rounds of standard chemotherapy; the cancer did not fully respond or came back after one or more rounds of rescue chemotherapy; or you are not able to have, have chosen not to have, or have relapsed after a stem cell transplant.
  • For lymphoma patients, at least one of these applies: after 4 rounds of standard chemotherapy, the tumor shrank less than 50% or got worse; the cancer went into full remission but came back within 6 months; the cancer has come back 2 or more times after full remission; or you cannot have, have chosen not to have, or have relapsed after a stem cell transplant — AND you have previously received both an anti-CD20 antibody treatment and a chemotherapy regimen containing a specific type of drug called an anthracycline.
  • Your cancer cells test positive for the CD19 and/or CD22 proteins, confirmed by lab testing.
  • Your doctor estimates you are likely to live for more than 3 months from the time you sign the consent form.
  • Your blood, liver, kidney, and heart function meet minimum required levels (confirm specific numbers with trial site).
  • Your overall physical fitness is rated 0, 1, or 2 on a standard medical scale, meaning you are able to carry out at least some daily activities.

Who may not be able to join:

  • You have serious heart problems, with your heart pumping at less than 50% of its normal capacity.
  • You have a history of severe lung disease or significantly reduced lung function.
  • You have another cancer that is at an advanced stage.
  • You have a severe or ongoing infection that cannot be brought under control.
  • You have a serious autoimmune disease or a condition where your immune system does not work properly from birth.
  • You have active hepatitis B or hepatitis C with abnormal liver function.
  • You have HIV or syphilis.
  • You have a history of severe allergic reactions to biological medicines, including antibiotics.
  • You received an donor stem cell transplant and still have an active immune reaction (called graft-versus-host disease) within one month of stopping immunosuppressant medications.
  • You have other serious physical or mental health conditions, or abnormal lab results, that the trial doctor believes could make participation unsafe or affect the trial results (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Heng Mei, M.D., Ph.D, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phone: 027-8572600

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Registry
ClinicalTrials.gov
Start date
4 November 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall response rate (ORR) of administering CD19&CD22 dual-target CAR-T cells In the treatment of relapsed/refractory B-cell hematologic tumors; Complete response rate (CR) of administering CD19&CD22 dual-target CAR-T cells In the treatment of relapsed/refractory B-cell hematologic tumors; Complete response with incomplete blood recovery rate (CRi) of administering CD19&CD22 dual-target CAR-T cells In the treatment of relapsed/refractory B-cell hematologic tumors; Partial response rate (PR) of administering CD19&CD22 dual-target CAR-T cells In the treatment of relapsed/refractory B-cell hemat...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov